27 Feb

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.

Quentis has been incubating for a few years within Highline Therapeutics, the New York biotech creator Versant Ventures formed in late 2015. Versant is one of the venture firms to… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

27 Feb

Blue biotechnologies – what are the challenges for the future? – 13 March 2018, BOULOGNE SUR MER, France

[Source: Research & Innovation] The oceans are a gold mine for marine technologies. They host a multitude of marine organisms with surprising properties that are precious resources for numerous applications in pharmacology, cosmetics, agro-food industry, energy sector and bio-remediation. How can these marine also known as blue biotechnologies, contribute to Blue Growth in a sustainable way? How can we enhance this important potential and appreciate the capacity of marine organisms to provide inputs to the blue economy without endangering them?
To exchange ideas, share experiences and express expectations, Nausicaa is pleased to invite you to a one-day event under the theme of Blue biotechnologies – what are the challenges for the future?
The event will take place on the 13th March 2018 in Boulogne sur Mer, France. The event is organised in the framework of the MARINA project funded by the European Commission’s Horizon 2020 programme and hosted by Nausicaa, National Sea Experience Centre.
It will bring together representatives from industry, researchers, policy makers, civil society and citizens. Together, they will share knowledge and expectations and propose a sustainable and integrated roadmap of actions based on Responsible Research and Innovation (RRI) dimensions: public engagement, gender balance, open access, science education, governance and ethics, in response to the triggering question: What Responsible Research and Innovation actions are needed to make marine biotech sustainable in France?

27 Feb

Biotech is key to Achieving International Trilateral Group’s Goals

This week in Geneva three key UN agencies are meeting to address and advance their shared mission of achieving the UN Sustainable Development Goals.

This is the seventh technical symposium organized by the WHO, WIPO and WTO dedicated to achieving the ambitious goals of UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages.

http://www.un.org/sustainabledevelopment/sustainable-development-goals/John Brennan, Secretary General of EuropaBio and a representative of the International Council of Biotechnology Associations, joined a panel discussion on Monday, February 26th at the symposium where he outlined the critical role biotechnology innovation will continue to play as we work to achieve the UN Sustainable Development Goals. Of note, John emphasized the need for greater support of policies that BIO recognizes as fundamental and vital elements of domestic and international policy that fuel innovation. This includes the need for improved and unified intellectual property protection standards and the reduction of trade barriers that impede access such as regulatory delays.

BIO share’s John’s view of the importance of working “together” with private and public institutions, as well as NGOs, to achieve the SDGs.

27 Feb

Global Separation Systems for Commercial Biotechnology Market Regional Outlook 2018 – Bio …

Global Separation Systems for Commercial Biotechnology Market outlook 2018 provides information to the user to analyze the future based demand and predicts the accurate implementations. The Global Separation Systems for Commercial Biotechnology Market Report contains data that is collected …

26 Feb

Vertex Pharma CMO Chodakewitz Retires, Kewalramani Named Successor

Jeffrey Chodakewitz, chief medical officer of Vertex Pharmaceuticals (NASDAQ: VRTX), is retiring. The Boston company said he will continue in an advisory role through early next year. Chodakewitz joined Vertex in 2014 as senior vice president. Reshma Kewalramani will step up as Chodakewitz’s successor effective April 1. Kewalramani joined Vertex in 2017 as senior vice president, late clinical development. Her experience also includes positions at Amgen (NASDAQ: AMGN). Vertex recently received FDA approval for cystic fibrosis combination drug ivacaftor/tezacaftor (Symdeko), the company’s third approved treatment for the inherited disorder.

UNDERWRITERS AND PARTNERS

          

          

            

26 Feb

FCH2 JU call for proposals 2018

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-JTI-FCH-2018-1Pillar: Societal ChallengesOpening Date: Deadline: Tue, 24 Apr 2018 17:00:00 (Brussels local time)Modification Date: Mon, 26 Feb 2018Latest information:

Normal
0

false
false
false

EN-GB
X-NONE
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.

26 Feb

Harnessing the Power of Nature: How Agrobacterium Has Advanced Food and Agriculture Innovation

Editor’s Note: As part of BIO’s 25th Anniversary celebration we will be spotlighting biotechnology innovations that have made a major impact over the past 25 years. This “Innovation Series” will publish on the 25th of every month throughout 2018. In the second installment we spotlight food and agriculture. 

On any given day, you can walk into any American grocery store and the produce section is overflowing with fresh fruits and vegetables. Similarly, shelf items like soybean and canola oil, cornstarch and sugar are never hard to come by. It’s hard to envision a time – outside a natural disaster – when these foods are not readily available.

These advances are the result of hardworking men and women across rural America who utilize decades of agriculture innovation to ensure that American consumers have healthy food for themselves and their families. And yet the battle to ensure food security for hundreds of millions of people in our world is far from won. So, how do we meet our future needs for food, fuel and fiber?

Already, biotechnology has dramatically improved the way in which we grow food.  Global acreage of biotech crops increased 110-fold over the past two decades (from 4.2 million acres in 1996 to 4.58 million acres in 2016) making it the fastest adopted crop technology in modern history.

The benefits provided by biotechnology have helped 18 million farmers increase crop productivity, conserve biodiversity, reduce chemical inputs, CO2 emissions, soil erosion and water use while providing societal gains and billions of meals – especially in the developing world.

What many don’t know, however, is that these advancements would not be possible without the discovery, and subsequent harnessing, of a soil microbe called Agrobacterium. Commonly found in nature, this microbe has the ability to move some of its genetic material into the roots – and into the DNA – of plants. As a result, the plant takes on the characteristics of the gene that has been transferred. This process has been occurring naturally in the environment since before man was in caves.

Fast forward to the late 1970s when scientist Mary-Dell Chilton, and a handful of others, began researching Agrobacterium, hypothesizing that the microbe could serve as a vehicle to insert desirable genes into plants. Essentially, the scientists believed that by removing some of the microbe’s genetic material that they didn’t want and putting in genetic material that they were interested in, they could effectively modify the plant as they wish. And unlike older methods for altering crops, such as traditional plant breeding, improvements made using Agrobacterium carried the promise of being faster, direct and more precise. A few years later, Chilton and her team affirmed this hypothesis when they successfully developed the first transgenic plant using this exciting new technique.

Not long after this discovery, scientists began experimenting further, modifying crops in ways that were beneficial to farmers, consumers and/or the environment. For example, scientists modified corn to contain proteins that made the crop resistant to caterpillars, much like the proteins sprayed on organic crops. Now known as B.t. corn, this modification allowed farmers to increase crop yields and dramatically lower their use of chemical insecticides.

Other crops have been modified to use less resources like water, which helps farmers cope with climate change. Additionally, some crops have been modified to carry extra nutrients like Vitamin A, which could have global impact on developing regions whose populations are malnourished.

Thanks to the discovery of Agrobacterium, there are 10 crops available today that have been improved through gene modification: corn, squash, cotton, soybean, papaya, alfalfa, sugar beets, canola, apple and the potato. Moreover, many of these crops are found in essential food items, such as canned vegetables, oils, sugars and soy-based milks and proteins.

In 2013, Chilton (Syngenta) along with two other scientists, Robert Fraley (Monsanto) and Marc Van Montagu (Institute of Plant Biotechnology Outreach at Ghent University in Belgium), received the World Food Prize for their work in discovering the capabilities of Agrobacterium. The award recognizes individuals who have improved the quantity and availability of food throughout the world.

At the award ceremony, then-Secretary of State John Kerry underscored the significance of the innovation, stating “we save money and we save the environment and we save lives. It is a virtuous cycle. And through innovation, we believe we can help alleviate the level of hunger and malnutrition today, but more than that, we can, hopefully, live up to our responsibilities for the future.”

As evidence by the crops on the market today, the exploitation of Agrobacterium has already had immeasurable impacts for farmers, consumers and the environment. And as Kerry alluded to in his address, biotechnology will continue to improve the way we grow food – and other necessary crops – for future generations.

26 Feb

Pharmaceutical & Biotechnology Environmental Monitoring Market: Production, Sales, Supply …

Pharmaceutical & Biotechnology Environmental Monitoring Market Research Report has the complete assessment of the latest trends of the Pharmaceutical & Biotechnology Environmental Monitoring market. The report focuses on the manufacturing challenges that are being faced and provides the …